Literature DB >> 10189270

Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.

A Sharma1, W F Ebling, W J Jusko.   

Abstract

A precursor-dependent model of indirect pharmacodynamic response which can describe tolerance and rebound was characterized in terms of the effects of changes in the fundamental properties of the drug on its response profiles. The model extends previous models by considering inhibition or stimulation of production of the response variable dependent on the amount of precursor which may accumulate or deplete after administration of some drugs. Standardized pharmacokinetic and pharmacodynamic parameters were used for generating dose, plasma concentration, and response-time profiles using computer simulations. The peak response (Rmax) and the time of its occurrence (TRmax) were dependent on the dose, degree of maximum inhibition (Imax) or stimulation (Smax), and drug concentrations causing 50% inhibition (IC50) or stimulation (SC50). The maximum rebound (RBmax) and the time of its occurrence (TRBmax) after a single bolus dose were also dependent on these factors, but were of lesser magnitude and showed relatively later occurrence. Interestingly, values of area between the baseline and effect curve (ABEC) and area between the baseline and rebound curve (ABRC) were equal for each set of conditions for each model, but the latter is reduced when there is a second pathway for loss of precursor. Tolerance occurs because of diverse mechanisms, and the response patterns demonstrated may be helpful in describing tolerance and rebound phenomena for drugs which affect precursor pools.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10189270     DOI: 10.1021/js980171q

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  58 in total

1.  Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

Review 2.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

3.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

4.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

5.  Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation.

Authors:  Franziska Schaedeli; Maria Pitsiu; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

6.  Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.

Authors:  Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

Review 7.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

8.  Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models.

Authors:  Anasuya Hazra; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

9.  Assessment of basic indirect pharmacodynamic response models with physiological limits.

Authors:  Zhenling Yao; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04       Impact factor: 2.745

Review 10.  Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.

Authors:  Robert M Straubinger; Wojciech Krzyzanski; Crystal M Francoforte; Jun Qu
Journal:  Anticancer Res       Date:  2007 May-Jun       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.